Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. - Wikidata - awgldk - TriplyDB

Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro.

Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro.

http://www.wikidata.org/entity/Q35551055

about

The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models.Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes Secukinumab for rheumatology: development and its potential place in therapy Extracorporeal shock waves down-regulate the expression of interleukin-10 and tumor necrosis factor-alpha in osteoarthritic chondrocytes Regulation and function of IL-17A- and IL-22-producing γδ T cells.Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis?Nitric oxide enhances aggrecan degradation by aggrecanase in response to TNF-alpha but not IL-1beta treatment at a post-transcriptional level in bovine cartilage explants.RANK, RANKL and osteoprotegerin in arthritic bone loss.Influence of infliximab on cytokines network and markers of bone remodeling in rheumatoid arthritis patients Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis.Pathologic finding of increased expression of interleukin-17 in the synovial tissue of rheumatoid arthritis patients.T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis Induction of Th17 lymphocytes and Treg cells by monocyte-derived dendritic cells in patients with rheumatoid arthritis and systemic lupus erythematosus Autoimmune diseases in the TH17 era.A potential role of myeloid DAP12-associating lectin (MDL)-1 in the regulation of inflammation in rheumatoid arthritis patients.Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement The role of T helper type 17 cells in inflammatory arthritis.Small molecule inhibitors of WNT/β-catenin signaling block IL-1β- and TNFα-induced cartilage degradation.Impact of inflammation on the osteoarthritic niche: implications for regenerative medicine.The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders.Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.Serum levels of IL-17, IL-4, and INFγ in Serbian patients with early rheumatoid arthritis.Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1.New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis.Potential route of Th17/Treg cell dynamics in targeting type 1 diabetes and rheumatoid arthritis: an autoimmune disorder perspective.Dextromethorphan Exhibits Anti-inflammatory and Immunomodulatory Effects in a Murine Model of Collagen-Induced Arthritis and in Human Rheumatoid Arthritis Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies.Interleukin-25 Produced by Synoviocytes Has Anti-inflammatory Effects by Acting As a Receptor Antagonist for Interleukin-17A Function.Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells.Association between severity of knee osteoarthritis and serum and synovial fluid interleukin 17 concentrations.Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy.Increased IL-17 expression in degenerated human discs and increased production in cultured annulus cells exposed to IL-1ß and TNF-α.Lapatinib ameliorates experimental arthritis in rats.Neutrophils produce interleukin-17B in rheumatoid synovial tissue.Tyrosine kinase inhibitor tyrphostin AG490 retards chronic joint inflammation in mice.Dynamic interaction between T cell-mediated β-cell damage and β-cell repair in the run up to autoimmune diabetes of the NOD mouse

P2860

Q24519770-62850AC7-53F4-4244-9E7B-1EB8F05CB7BB Q24800545-873816A9-6B15-484D-8C9C-14D0E3D2BF5B Q26738523-9467A170-3878-4342-8A27-DAA45F54CD00 Q33317619-6E978D8A-FAE8-4AB9-AB58-4CDF43B72676 Q35154002-6DB13316-EC46-430E-96D5-F3AD5772C314 Q35617683-6EDE2E6C-C74B-4F76-B334-09EFDB4C994F Q35675887-46BBD8E0-0BF2-4A23-BC19-3F43209444AA Q35686603-FCB9E632-F651-494F-80CE-809BA9692D7A Q36078073-60E165E7-61A6-405D-9B05-96FB721DC26A Q36463967-19D41103-2368-4CA9-BEA5-8505199A5ECF Q36622363-8DE0D808-B580-4059-A1C8-1E194B5306F9 Q36956216-55D9A9B2-F942-4478-9591-5C489CD16B91 Q37129568-AD626F7B-076A-4221-B413-DAB0F6E63876 Q37316252-2A77BCAB-914A-4475-B5FB-E9FCC492D9BE Q37486130-ABD93A3F-1A0C-4AA0-B76B-8AA01F2A8245 Q37500085-B87410DD-9541-4066-A77F-1D0D67E07FA5 Q37522254-8832E5EC-90E0-4E04-923A-D6F31A153EC3 Q37598359-456FFB5F-4FA5-4A1D-9C2C-2C7E80A3C363 Q37690284-874721AA-991D-414E-B725-1BAE13D8C6DE Q38027919-8384CD5C-BBAE-4E4D-9ED1-5FA15178161D Q38101877-276CB0D4-C8C4-4B57-80F4-728D48CFD7C1 Q38118781-24481EB7-1FE2-4E36-99A3-CBEA20F533DA Q38425628-F06DE516-F174-430D-83D0-86DA3F757237 Q38594831-1FF145D6-5D9F-4E43-BC56-50A46F6C3C1E Q38799600-96DAA138-4851-421D-A5FD-68112DBF577D Q39027725-8971B4B0-3B7C-4B65-9721-C39E7AEF4830 Q41200262-C9E0DBD3-DFF8-4621-934B-F648B9226BD3 Q42136310-C4C9E0A1-D32E-4C5C-A01F-C68709118210 Q42236975-9172170C-5ADF-415B-A60E-AFC181E58BB4 Q43251968-616A23A1-F47B-45DD-B6BD-DCCD4D6BA056 Q46193783-584506ED-1D19-4698-B81A-ECD365ED0E35 Q46941367-300C4666-0ED2-4DC6-90FF-3A31389BE584 Q51032609-3DC61B53-FFE2-4841-93D8-3647E6E9E5B7 Q51108993-CB46A3D8-4BD9-4D03-9B23-15E43992BD02 Q54242443-58F8B06D-78B2-4587-9708-48253D2035C2 Q54381367-E8EB772F-6382-488A-937A-3D262CFCE7F1 Q56981883-7141060F-DD8F-4F45-9A52-C5AADA92224A

P2860

Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro.

http://www.wikidata.org/entity/Q35551055

description

2002 nî lūn-bûn

@nan

2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Interleukin 17 synergises with ...... artilage destruction in vitro.

@ast

Interleukin 17 synergises with ...... artilage destruction in vitro.

@en

type

label

Interleukin 17 synergises with ...... artilage destruction in vitro.

@ast

Interleukin 17 synergises with ...... artilage destruction in vitro.

@en

prefLabel

Interleukin 17 synergises with ...... artilage destruction in vitro.

@ast

Interleukin 17 synergises with ...... artilage destruction in vitro.

@en

P1433

Q35551055-900E028B-F473-4CFC-B6CA-3C5959D8D167

P1476

Q35551055-27C10456-38A1-4422-A175-002CF0910255

P2093

Q35551055-3F26BE31-023E-460E-A9FA-D93B82D92AFA

Q35551055-80404027-425A-45B9-8431-D97E0ED3B328

Q35551055-D4B49E48-5C09-4E62-B5BD-700DB00F1F60

Q35551055-DB6438A5-7666-4EE9-8E22-95FF93D5D3E0

P2860

Q35551055-08ED1ADB-162E-49F4-8361-B62D0EC2BC57

Q35551055-14120C0C-02D3-4464-9AE9-338A7CE3EE2F

Q35551055-16F5E8B0-9024-4DD2-8B1C-3EF744C7242B

Q35551055-1EBF41F8-F43E-4764-AB48-2E0B589598E0

Q35551055-2716FF4B-1A7A-4E23-9CC6-5F6E812E277F

Q35551055-2ABF5F59-B676-4374-9565-640FCC15D837

Q35551055-2D3BDF32-742F-4012-AC12-8C8B4BA7CA44

Q35551055-373032FD-3344-4C26-9086-DF51A7FBBED1

Q35551055-51DA1639-2886-438B-ABA4-73908531B4BC

Q35551055-5A9842E0-284F-4F04-A79E-CEBE77EFF4AB

P304

Q35551055-29126494-B2F1-4885-B48F-870D0A62CCF4

P31

Q35551055-4760BC39-2007-4A65-B03E-75E6F784CC7B

P356

Q35551055-57F77F79-48BF-4078-AB4A-5E936CB9D9CE

P407

Q35551055-02DF83F6-AC00-4682-B0F9-AF4F328B3833

P433

Q35551055-63000D6E-0F78-4302-8183-D0019E46FC9D

P478

Q35551055-62650C01-9943-4D21-87C4-BBCCB111A279

P577

Q35551055-A669E550-1604-4385-8776-62789481B790

P5875

Q35551055-1825D2EE-9F0D-4B42-AABA-7DDF19DCFFF4

P698

Q35551055-05DC7EEC-D1E0-41CB-A8ED-D2892D0E830E

P921

Q35551055-08E34C9E-AE2B-452C-AED7-EB25DA610D37

Q35551055-935a12db-7305-46f5-9e9a-25bf8c8913aa

P932

Q35551055-8AE74BF5-D570-4617-AACE-023412F49D2E

P356

P1433

Annals of the Rheumatic Diseases

P1476

Interleukin 17 synergises with ...... artilage destruction in vitro.

@en

P2093

Löwik CW

http://www.w3.org/2001/XMLSchema#string

Papapoulos SE

http://www.w3.org/2001/XMLSchema#string

Van Bezooijen RL

http://www.w3.org/2001/XMLSchema#string

Van Der Wee-Pals L

http://www.w3.org/2001/XMLSchema#string

P2860

IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis

IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis

Pathogenesis of joint damage in rheumatoid arthritis.

The role of nitric oxide in articular cartilage damage.

Marimastat (BB2516): current status of development.

T cells: pathogenic cells and therapeutic targets in rheumatoid arthritis.

Role of tumour necrosis factor alpha in experimental arthritis: separate activity of interleukin 1beta in chronicity and cartilage destruction

Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis.

Are T cells in rheumatoid synovium aggressors or bystanders?

High in vivo expression of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis patients.

P304

870-876

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.61.10.870

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11161901

http://www.w3.org/2001/XMLSchema#string

P698

12228154

http://www.w3.org/2001/XMLSchema#string

P921

P932

1753923

http://www.w3.org/2001/XMLSchema#string